Day: March 1, 2021

RENO, Nev. , March 01, 2021 (GLOBE NEWSWIRE) — Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”) issued the following statement in response to a March 1, 2021 write up by Hindenburg Research LLC (“Hindenburg”). Hindenburg is a self-proclaimed short seller who we believe stands, along with its clients, to realize significant gains in the event that Ormat’s stock price declines.Hindenburg’s claims are inaccurate and filled with innuendo in an attempt to mislead investors about Ormat.We have been providing clean renewable energy in Kenya, Honduras and Guatemala for many years, supporting local communities. Our facilities are financed by numerous leading multinational banks, which conduct extensive due diligence on the Company and its operations prior to entering into lending agreements. We are committed to conducting...

PHOENIX, March 01, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the launch of an underwritten, secondary offering (the “Offering”) of 10,750,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares are being offered by the Company’s principal shareholder, Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”). The Selling Stockholder expects to grant the underwriter a 30-day option to purchase up to an additional 1,612,500 shares. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering.Morgan Stanley is acting as sole underwriter...

EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.“Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we are eagerly anticipating objective response rate and other important data from ILLUMINATE-301, our pivotal registration trial in anti-PD-1 refractory advanced melanoma, later this month,” stated Vincent Milano, Idera’s Chief Executive Officer. “I’m very proud of our team’s resiliency and tenacity as they work diligently toward that goal, as well as the ongoing work in ILLUMINATE-206, our trial in micro-satellite stable colorectal cancer. In addition, we are in a healthy financial position and expect our current cash to fund our activities...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 01, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has entered into an agreement with Cantor Fitzgerald Canada Corp., as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 34,500,000 units of the Company (the “Units”) at a price of $0.58 per Unit for gross proceeds of $20,010,000 (the “Offering”).Each Unit will be comprised of one common share in the...